200 related articles for article (PubMed ID: 16467096)
1. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
Gomez HL; Santillana SL; Vallejos CS; Velarde R; Sanchez J; Wang X; Bauer NL; Hockett RD; Chen VJ; Niyikiza C; Hanauske AR
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):832-8. PubMed ID: 16467096
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed disodium (Eli Lilly).
Norman P
Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
4. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
5. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
8. [Pemetrexed].
Sudoh J; Gemma A
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Calvert H
Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D
Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230
[TBL] [Abstract][Full Text] [Related]
12. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
13. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
15. Translational research with pemetrexed in breast cancer.
Hanauske AR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):66-9. PubMed ID: 15655941
[TBL] [Abstract][Full Text] [Related]
16. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.
Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hoffmann S; Hanauske-Abel H; Ma D; Chen V; Paoletti P; Niyikiza C
Invest New Drugs; 2007 Oct; 25(5):417-23. PubMed ID: 17534577
[TBL] [Abstract][Full Text] [Related]
17. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
Capiaux GM; Budak-Alpdogan T; Alpdogan O; Bornmann W; Takebe N; Banerjee D; Maley F; Bertino JR
Cancer Gene Ther; 2004 Dec; 11(12):767-73. PubMed ID: 15359285
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
[No Abstract] [Full Text] [Related]
19. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]